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Non-syndromal X-linked intellectual disability (NS-XLID) represents a broad group of
clinical disorders in which ID is the only clinically consistent manifestation. Although
in many cases either chromosomal linkage data or knowledge of the >100 existing
XLID genes has assisted mutation discovery, the underlying cause of disease remains
unresolved in many families. We report the resolution of a large family (K8010) with NS-
XLID, with variable macrocephaly and macro-orchidism. Although a previous linkage
study had mapped the locus to Xq12-q21, this region contained too many candidate
genes to be analyzed using conventional approaches. However, X-chromosome exome
sequencing, bioinformatics analysis and segregation analysis revealed a novel missense
mutation (c.1012C>T; p.R338W) in ARHGEF9. This gene encodes collybistin (CB), a
neuronal GDP-GTP exchange factor previously implicated in several cases of XLID, as
well as clustering of gephyrin and GABAA receptors at inhibitory synapses. Molecular
modeling of the CB R338W substitution revealed that this change results in the
substitution of a long electropositive side-chain with a large non-charged hydrophobic
side-chain. The R338W change is predicted to result in clashes with adjacent amino
acids (K363 and N335) and disruption of electrostatic potential and local folding of the
PH domain, which is known to bind phosphatidylinositol-3-phosphate (PI3P/PtdIns-
3-P). Consistent with this finding, functional assays revealed that recombinant CB
CB2 R338WSH3 was deficient in PI3P binding and was not able to translocate EGFP-−
gephyrin to submembrane microaggregates in an in vitro clustering assay. Taken
together, these results suggest that the R338W mutation in ARHGEF9 is the underlying
cause of NS-XLID in this family.
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INTRODUCTION
Intellectual disability (ID) is characterized by significantly
impaired intellectual and adaptive function, and is often
defined by an IQ score below 70 in addition to deficits in
two or more adaptive behaviors (e.g., social skills, problem
solving) that affect everyday life. ID is also subdivided into
syndromal ID, where ID is associated with other clinical,
morphological, or behavioral symptoms or non-syndromal
ID, where intellectual deficits appear without other associated
defects (Stevenson et al., 2012). X-linked intellectual disability
(XLID) refers to forms of ID typically associated with X-
linked recessive inheritance. Mutations in monogenic XLID
have been reported in >100 genes, many of which are now
used in routine diagnostic screening panels (Basehore et al.,
2015). Despite screening for mutations in selected known
XLID genes by conventional linkage/candidate gene analysis
or array CGH for examining copy number variants (CNVs),
large number of families mapping to the X-chromosome
remained unresolved (Lubs et al., 2012). These cases either
represent undiscovered disease-relevant mutations in known
genes, or causal mutations in novel XLID loci that remain to be
identified.
Mutation and gene discovery in XLID has recently been
transformed by large-scale DNA sequencing approaches coupled
with stringent variant filtering (Tarpey et al., 2009; Rauch
et al., 2012; Gilissen et al., 2014; Redin et al., 2014; Hu
et al., 2015; Niranjan et al., 2015; Tzschach et al., 2015).
For example, a recent study in a large cohort of unresolved
families with XLID revealed that 20% of families carried
pathogenic variants in established XLID genes (Hu et al.,
2015), as well as revealing seven novel XLID genes (CLCN4,
CNKSR2, FRMPD4, KLHL15, LAS1L, RLIM, and USP27X)
and two candidates (CDK16 and TAF1). Another strategy,
known as Affected Kindred/Cross-Cohort Analysis (Niranjan
et al., 2015) has also identified variants in known and novel
XLID genes including PLXNA3, GRIPAP1, EphrinB1 and
OGT. However, analysis of next-generation data sets has also
highlighted a number of XLID genes where truncating variants
or previously published ‘‘mutations’’ are observed at a relatively
high frequency in normal controls, calling into question whether
certain single nucleotide variants (SNVs) are indeed causal
(Tarpey et al., 2009; Piton et al., 2013). This highlights the
need for integrating structure-function based approaches into
the analysis pipeline for validating potentially disease-causing
variants.
In this study, we have combined next-generation sequencing,
variant filtering and structure-function assays to resolve the
cause of XLID in a large family (K8010) with NS-XLID, with
variable macrocephaly and macro-orchidism (Johnson et al.,
1998). The previous clinical study in this family revealed ten
affected males and two affected females in two generations, as
well as four obligatory carriers. Most affected males exhibited
macrocephaly and macro-orchidism, which are typical signs
of the fragile X syndrome. However, cytogenetic testing and
analysis of FMR1 indicated they did not have this syndrome.
It was also notable that some normal males in the family
also exhibited macro-orchidism and macrocephaly. Linkage
analysis suggested that the causative gene was located on
Xp11-q21 (Johnson et al., 1998). We present compelling
evidence that the likely cause of XLID in this family is
a missense mutation in ARHGEF9, encoding a neuronal
RhoGEF known as collybistin (CB) involved in both inhibitory
synaptic organization and mammalian target of rapamycin




Family K8010 was previously reported by Johnson et al. (1998).
Briefly, the males resembled those with fragile X syndrome in
that they had macrocephaly (abnormally large head, typically
2.5 standard deviations above normal for weight and gender),
macro-orchidism (abnormally large testes), blue eyes, prominent
jaw and long facies. Additionally, one carrier female was
described as being ‘‘slow’’. However, using linkage analysis, the
locus was mapped to Xq12-q21 rather than Xq27.3. Additionally,
FMR1 gene analysis was negative (Johnson et al., 1998).
Exon Capture and DNA Sequencing
Next generation sequencing was conducted as a partial follow-
up of 15 probands from a large scale sequencing of 718
X-chromosome genes in 208 XLID probands (Tarpey et al.,
2009). The deep sequencing was conducted using the Agilent
SureSelect Human X chromosome kit (Takano et al., 2012).
A novel and unique mutation in ARHGEF9, c.1012C>T, was
noted in K8010. Segregation analysis was conducted using Sanger
sequencing.
Polymorphism Analysis
Screening of 566 normal individuals (420 males, 146 females)
for the ARHGEF9 c.1012C>T variant was carried out using
allele-specific amplification. Primers used were: ARHGEF9-
ASOF 5′-TACGGCCGCAACCAGCtGt 3′ and ARHGEF9-
ASOR 5′-CCCATCAGTATTTGCCCACT-3′. The ASOF primer
recognized the mutation, which is indicated by the ‘‘t’’ at the
3′ end of the primer. The third base from the 3′ end was also
changed from an ‘‘a’’ to a ‘‘t’’ to increase the specificity of
the PCR. The ASOR primer was designed so that the Tm of
both primers were similar and to generate a PCR product of
above 500 bp. Gradient duplex PCR analysis was conducted
using mutation and normal samples to choose the optimum
annealing temperature. High-throughput duplex PCR analysis
with a mutation and normal sample as positive and negative
controls.
Molecular Modeling of the Collybistin
R338W Mutation
The non-synonymous R338W substitution was modeled into
the structure of rat CB (PDB 2DFK; Xiang et al., 2006)
using the swapaa command in Chimera (Pettersen et al.,
2004) using the Dunbrack backbone-dependent rotamer library
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(Dunbrack, 2002). This took into account the lowest clash
score, highest number of H-bonds and highest rotamer
probability. Electrostatic potential of wild-type and R338W
mutant CB was calculated using the Adaptive Poisson-
Boltzmann Solver (APBS) web server (Baker et al., 2001;
http://www.poissonboltzmann.org/).
Site-Directed Mutagenesis and Expression
Constructs
Full-length human CB cDNAs were cloned into the vector pRK5
as previously described (Kalscheuer et al., 2009). Mutations
were introduced into pRK5myc-hCB3SH3− construct using
the QuikChange site-directed mutagenesis kit (Agilent) and
confirmed by Sanger DNA sequencing of the entire coding
region.
PI3P Pull-Down Assays
Human embryonic kidney (HEK293) cells were grown in
DMEM supplemented with 10% (v/v) fetal bovine serum at
37◦C, 5% CO2 and transfected with 4 µg pRK5myc-hCB3SH3−
wild-type or R338W mutants using FuGENE (Roche). After
24 h, transfected cells were solubilized in a buffer containing
Triton X-100 (Sigma-Aldrich), 1%; 150 mM NaCl; 50 mM Tris,
pH 7.4, with protease inhibitor cocktail (Roche, Sussex, UK).
Insoluble material was removed by centrifugation at 16, 100× g
for 20 min. Phosphatidylinositol-3-phosphate (PI3P/PtdIns-3-P)
agarose beads (40 µl; Eschelon Biosciences) were incubated
with cell lysates for 2 h at 4◦C. Beads were washed four
times in buffer. Proteins were eluted from beads by heating
at 98◦C for 3 min in 2 × sample loading buffer and then
subjected to SDS-PAGE. Proteins binding to beads were
detected by Western blotting using mouse anti-c-myc antibody
(Sigma, 1:1000) and HRP-conjugated goat anti-mouse (Santa
Cruz, 1:2000). Immunoreactivity was visualized using West
Pico Chemiluminescent Substrate (Pierce). Expression levels
of hCB3SH3− and hCB3SH3−R338W, and PI3P pulldown assay
results were assessed using an unpaired, two-tailed Student’s
t-test.
Gephyrin Clustering Assays
These were performed essentially as previously described
(Harvey et al., 2004). HEK293 cells were co-transfected
with pRK5myc-hCB3SH3− wild-type, pRK5myc-hCB3SH3+
wild-type, pRK5myc-hCB3SH3− R338W, pRK5myc-hCB3SH3−
R290H or pRK5myc-hCB3SH3− R356N/R357N constructs at
a 1:1 ratio with pEGFP-gephyrin using electroporation (Gene
Pulser II, Bio-Rad). Cells were fixed after 24 h for 2 min in
4% (w/v) PFA in PBS. Immunostaining to detect CB was
performed using a mouse anti-c-myc antibody (1:200, Sigma)
and detected using an AlexaFluor 546 goat anti-mouse secondary
antibody (1:600; Invitrogen). Counterstaining for cell nuclei
was performed with DAPI (1:500; Life Technologies). Confocal
microscopy was performed using a Zeiss LSM 710 META. All
images were taken with a× 63 objective.
RESULTS
Identification of a R338W Mutation in
ARHGEF9 in Family K8010
X-chromosome exome sequencing of an individual male
in family K8010 followed by bioinformatics analysis and
filtering against publicly-available datasets revealed a
novel missense change in ARHGEF9, chrX:62,885,810G>A,
c.1012C>T; p.R338W, predicted as probably damaging
(PolyPhen-2, score 1.000), damaging (SIFT) and a
Combined Annotation Dependent Depletion (CADD)
score of 19.37 (possibly pathogenic). This suggested
that this missense mutation could be responsible for
XLID, macrocephaly and macro-orchidism in this family.
Subsequent segregation analysis using Sanger DNA sequencing
indicated that the ARHGEF9 c.1012C>T variant co-
segregated with the phenotype in all individuals tested
(Figures 1A,B).
Collybistin Mutation R338W is Predicted to
Disrupt PH Domain Folding
CB belongs to the Dbl family of guanine nucleotide exchange
factors, occurs in multiple splice variants (Kins et al., 2000;
Harvey et al., 2004) and is specific for Cdc42, a small GTPase
belonging to the Rho family (Xiang et al., 2006). CB has a
multi-domain structure consisting of a regulatory SH3 domain,
a catalytic RhoGEF domain and a pleckstrin homology (PH)
domain (Figure 1C). Residue R338W is the first reported
ARHGEF9 missense mutation affecting a highly conserved
residue in the PH domain (Figure 1D). Previous nonsense
and missense mutations in CB have affected residues in the
N-terminus (p.Q2X; Shimojima et al., 2011), regulatory SH3
domain (p.G55A; Harvey et al., 2004) and catalytic RhoGEF
domain (p.R290H; Lemke et al., 2012; Papadopoulos et al.,
2015). To assess how the R338W substitution might disrupt
CB function, molecular modeling was performed using the
structure of rat CB (PDB 2DFK; Xiang et al., 2006), which has a
sequence identity of 85.5% to human CB [aligned using HHalign
algorithm (Söding, 2005) within Clustal-Omega (Sievers et al.,
2011)]. The R338W change replaces a long, electropositive
side-chain (arginine) with a large non-charged, hydrophobic
side-chain (tryptophan). Positively-charged residues are thought
to be critical for interaction of the PH domain with the
membrane (Xiang et al., 2006) and R338W clearly changes
the electrostatic potential of the PH domain, as visualized
using APBS (Figures 2A–C). R338W is also predicted to
introduce a number of clashes with surrounding residues
(e.g., N335, K363; Figures 2D,E), which is also predicted to
affect interactions with membrane and the fold of the PH
domain.
Mutation R338W in Collybistin Disrupts
Phosphatidylinositol-3-Phosphate Binding
The CB PH domain has previously been shown to play a
key role in binding PI3P/PtdIns-3-P, a phosphoinositide
with an emerging role in membrane trafficking and signal
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FIGURE 1 | Identification of a R338W mutation in ARHGEF9 in family K8010. (A) Pedigree of the K8010 family, which has been updated. Open symbols
represent normal individuals, filled squares represent affected males. Individuals tested for the nucleotide substitution in each family are indicated with either a T
(mutant allele) or a C (normal allele). (B) DNA sequence electropherograms for the c.1012C>T mutation reported in this study. (C) Schematic of the human collybistin
(CB) protein with a regulatory SH3 domain, a catalytic RhoGEF domain and a pleckstrin homology (PH) domain. The relative locations of known missense and
nonsense mutations in ARHGEF9 are shown. (D) Sequence alignments of CB proteins from various species showing the high conservation of R338W in the PH
domain. Note that R338W is not one of the known PI3P binding residues (R356 and R357, green).
transduction. Deletion of the CB PH domain, or mutation
of two key arginine residues (R356/R357) involved in PI3P
binding has been demonstrated to abolish CB-mediated
gephyrin clustering in functional assays (Harvey et al., 2004;
Kalscheuer et al., 2009; Reddy-Alla et al., 2010). In order
to determine whether the R338W mutation affected CB
binding to PI3P, we performed pulldown assays using PI3P
immobilized on agarose beads incubated with lysates of
HEK293 cells transfected with either wild-type CB variant
CB3SH3− or mutant CB3SH3−R338W. Total expression of
CB3SH3−R338W was not significantly different to wild-type
CB3SH3− when normalized to β-actin expression (Figure 3A,
left and right panels, wild-type CB2SH3− 1.00 ± 0.23 vs.
R338W 1.16 ± 0.33; normalized to wild-type ± SEM,
n = 5). However, when the PI3P pull-down fraction was
expressed as a percentage of raw input, a significant reduction
of PI3P binding was observed for the R338W variant
(Figure 3A, middle and right panels, wild-type 100 ± 13.5
vs. R338W 38 ± 8.6; pull-down fraction ± SEM, n = 5,
p< 0.006).
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FIGURE 2 | The R338W substitution is predicted to influence the
electrostatic potential and folding of the CB PH domain. (A) Arginine
338 is located on the surface of the CB structure within the pleckstrin
homology (PH) domain (circled by a black dotted line). It resides within a cleft
between turns of β-sheet secondary structure (D), in close proximity to other
electropositive side-chains. Therefore, an area of hydrophobicity is created
(B) close to the polar heads of the cell membrane. It is predicted that
substitution of arginine with tryptophan at position 338 changes the
hydrophobicity of this area, making it neutral in charge (C). In addition, the
bulky side-chain of tryptophan introduces clashes with surrounding side
chains of lysine 363 and asparagine 335 (E), disrupting the overall structure of
the protein in this region.
Mutation R338W Disrupts
Collybistin-Mediated Gephyrin Clustering
Given the key role of CB in mediating gephyrin clustering at
inhibitory synapses, we also investigated whether the R338W
substitution affected the ability of CB to translocate gephyrin
to submembrane microaggregates in a cellular clustering assay
(Harvey et al., 2004; Kalscheuer et al., 2009). This involved co-
expression of myc-tagged human CB (myc-CB3SH3−; Kalscheuer
et al., 2009) with EGFP-gephyrin in HEK293 cells. CB variants
containing the regulatory SH3 domain (CB3SH3+) typically co-
localize with EGFP-gephyrin in large intracellular aggregates
(Figures 3B,D; Kins et al., 2000; Harvey et al., 2004; Kalscheuer
et al., 2009) and require neuroligins, GABAAR α2 or the small
Rho-like GTPase TC10 for activation (Poulopoulos et al., 2009;
Saiepour et al., 2010; Mayer et al., 2013). However, variants
lacking the regulatory SH3 domain (e.g., CB3SH3−) typically
result in the formation of EGFP-gephyrin submembrane clusters
(Figure 3C). However, the CB3SH3−R338W variant did not
result in the formation of submembrane microaggregates with
EGFP-gephyrin, but rather co-localized with EGFP-gephyrin
in large intracellular aggregates (Figure 3E) similar to the
distribution previously observed for CB3SH3+ or CB mutants
that disrupt PI3P binding, such as R290H and the double
mutant R356N/R357N (Figures 3F,G; Reddy-Alla et al., 2010;
Papadopoulos et al., 2015). This demonstrates that the R338W
substitution disrupts CB-mediated accumulation of gephyrin in
submembrane microclusters.
DISCUSSION
This study reports the identification and functional
characterization of a novel mutation (p.R338W) in ARHGEF9
that is likely to represent the cause of XLID in family
K8010. Using next-generation X-exome sequencing, Affected
Kindred/Cross-Cohort Analysis and inheritance testing, we
found a novel SNV (c.1012C>T; p.R338W) in ARHGEF9
that segregated with the disease phenotype. Using molecular
modeling and functional assays for CB PI3P binding and
gephyrin clustering, we were able to establish the likely
pathomechanism for p.R338W: a local disruption in the PH
domain structure, leading to a reduction in PI3P binding
and/or PH domain folding, and consequent loss in the ability
of CB to mediate gephyrin clustering in an in vitro assay. The
identification of ARHGEF9 as the causative gene for family
K8010 is consistent with previous studies that have identified CB
as a neuronally-expressed RhoGEF with a key role in inhibitory
synaptic transmission (Kins et al., 2000; Harvey et al., 2004).
At selected inhibitory synapses, CB interacts with gephyrin
(Kins et al., 2000; Harvey et al., 2004), a scaffolding protein with
dual roles in inhibitory receptor clustering and molybdenum
co-factor synthesis (Feng et al., 1998). CB knockout mice show
increased anxiety and impaired spatial learning associated with
a selective loss of GABAARs in the basolateral amygdala and
hippocampus (Papadopoulos et al., 2007). Unsurprisingly, loss of
CB clearly leads to significant changes in GABAergic inhibition,
network excitability and synaptic plasticity (Jedlicka et al., 2009).
Recent studies have also implicated CB in mTOR signaling: CB
physically interacts with mTOR and inhibits mTORC1 signaling
pathway and protein synthesis (Machado et al., 2015). This
suggests that disruption of mTORC1 signaling pathways could
also contribute to ID in patients with ARHGEF9 loss-of-function
mutations.
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FIGURE 3 | R338W reduces collybistin PI3P binding and prevents formation of collybistin-mediated submembrane gephyrin clusters in cellular
assays. (A) Human embryonic kidney (HEK293) cells were transfected with plasmids encoding myc-CB3SH3− or myc-CB3SH3−R338W and cell lysates incubated with
PI3P-conjugated agarose beads. After washing, bound material was subjected to SDS-PAGE and analyzed by immunoblotting with an anti-myc antibody (Sigma).
Notably, no significant difference was observed in total level of myc-CB3SH3−R338W expression in comparison with wild-type CB3SH3−, using β-actin as a loading
control (A, left and right panels, normalized to wild-type 1.00 ± 0.23 vs. R338W 1.16 ± 0.33; wild-type ± SEM, n = 5). myc-CB3SH3−R338W binding to PI3P was
significantly reduced (62.7% ± 3.9%) in comparison to wild-type CB3SH3−. When we assessed the PI3P pull-down fraction as a percentage of the raw input, we saw
a significant difference between wild-type and the R338W variant (A, middle and right panels; wild-type 100 ± 13.5 vs. R338W 38 ± 8.6; pull-down fraction ± SEM,
n = 5, ∗∗p < 0.006, unpaired student’s t-test). No β-actin immunoreactivity was observed in PI3P pull-down samples, confirming the validity of this assay. (B–G)
HEK293 cells were co-transfected with EGFP-gephyrin alone (B), or with myc-CB3SH3− (C), myc-CB3SH3+ (D), myc-CB3SH3−R338W (E), or the PI3P binding defective
mutants myc-CB3SH3−R290H (F), and myc-CB3SH3−R356N/R357N (G). Cells were immunostained using anti-myc and AlexaFluor 546 antibodies and co-stained with a
nuclear marker (DAPI). Note that while myc-CB3SH3− co-localizes with gephyrin in submembrane clusters, all other CB variants co-localize with gephyrin in large
intracellular aggregates, consistent with a lack of CB-mediated gephyrin clustering activity. Scale bar = 10 µm. (C) is a Z-projection, all other images are single plane.
A number of mutations in ARHGEF9 have been identified
in patients encompassing missense and nonsense mutations,
deletions and complex rearrangements (Table 1). Curiously,
the associated phenotypes vary quite substantially. For example,
Harvey et al. (2004) reported a p.G55A missense mutation
in ARHGEF9 associated with hyperekplexia, early infantile
epileptic encephalopathy and severe psychomotor retardation
(p.G55A, SH3 domain). By contrast, Shimojima et al. (2011)
identified an ARHGEF9 nonsense mutation (p.Q2X) in an
individual with refractory seizures, right frontal polymicrogyria
and severe psychomotor retardation. Lemke et al. (2012) also
reported a p.R290H missense mutation in the CB RhoGEF
domain associated with epilepsy and ID. Furthermore, large
de novo deletions affecting ARHGEF9 as well as neighboring
genes SPIN4 and LOC92249 have been reported to be
associated with complex phenotypes that include features
such as partial seizures, delayed psychomotor development
and generalized overgrowth (Table 1; Lesca et al., 2011;
Shimojima et al., 2011). Lastly, a balanced chromosomal
translocation (Kalscheuer et al., 2009) and a paracentric
inversion (Marco et al., 2008) have been reported with yet
more clinical features, including disturbed sleep-wake cycle,
increased anxiety and aggressive behavior or hyperarousal,
respectively.
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TABLE 1 | ARHGEF9 mutations and associated phenotypes.
Mutation type Nucleotide Protein Reported phenotype Reference
Missense and c.4C>T p.Q2X Refractory seizures, right frontal polymicrogyria, Shimojima et al. (2011)
nonsense mutations severe psychomotor retardation, ataxia
c.869G>A p.G55A Hyperekplexia, early infantile epileptic encephalopathy Harvey et al. (2004)
and severe psychomotor retardation
c.869G>A p.R290H Epilepsy and intellectual disability Lemke et al. (2012)
c.1012C>T p.R338W Intellectual disability with variable macrocephaly This study
and macro-orchidism
Deletions De novo 737 kb deletion including Complex partial seizures, severely delayed Kalscheuer et al. (2009)
ARHGEF9, SPIN4, LOC92249 psychomotor development, generalized
overgrowth and trigonocephaly
De novo 1.29 Mb deletion of Xq11.11 Delayed psychomotor development, loss of consciousness, Marco et al. (2008)
including ARHGEF9, SPIN4, LOC92249 hypotonia, cyanosis, generalized overgrowth, mild
dysmorphic features, hyperactivity with attention
deficit, limited social interaction
Complex rearrangements Balanced translocation 46, X, Disturbed sleep-wake cycle, Kalscheuer et al. (2009)
t(Xq11.1;18q11.21) late-onset epileptic seizures, increased anxiety,
aggressive behavior and intellectual disability
Balanced de novo paracentric Hyperarousal (noise and social situations), Marco et al. (2008)
inversion (X)(q11.1;q27.3) global developmental delay, dysarthric speech, difficulty
with smooth eye pursuit, bilateral lower extremity spasticity,
brisk reflexes and extensor plantar responses, wide-based gait
The exact reasons behind this clinical variability remains
unknown, but are likely to be linked to several factors.
Firstly, certain CBmutations (e.g., p.G55A, p.R290H, C-terminal
truncations) clearly cause dominant-negative effects on gephyrin
and GABAA receptor clustering in neuronal systems (Harvey
et al., 2004; Kalscheuer et al., 2009; Papadopoulos et al., 2015).
Secondly, for female patients with CB mutations, the clinical
features observed may depend on the degree of X-inactivation
skewing. At least two studies involving a translocation or
inversion in ARHGEF9 have indicated skewed X inactivation
in favor of the abnormal X chromosome (Marco et al., 2008;
Kalscheuer et al., 2009). However, one emerging theme in
functional studies of CB missense mutations appears to be loss
of PI3P binding. Our own functional analysis suggests that the
p.R338W variant causes a local disruption in the PH domain
structure, leading to a reduction in PI3P binding and/or PH
domain folding, and consequent loss in the ability of CB to
mediate gephyrin clustering. Similar findings have recently been
reported for the p.R290H mutation linked to epilepsy and ID,
which appears to alter the strength of intramolecular interactions
between the RhoGEF and PH domains, also leading to a loss of
PI3P binding affinity (Papadopoulos et al., 2015). These results
highlight the key role of phosphoinositide binding and correct
localization of CB for synaptic function. However, given the
variability in clinical phenotypes associated with CBmutations, it
is also evident that next-generation sequencing diagnostics have
a pivotal role to play in the diagnosis of X-linked disorders.
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